Z Voysey1, S V Fazal2, A S Lazar3, R A Barker4. 1. Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK. zv214@cam.ac.uk. 2. Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK. 3. Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK. 4. Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, WT-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Abstract
INTRODUCTION: Mounting evidence supports the existence of an important feedforward cycle between sleep and neurodegeneration, wherein neurodegenerative diseases cause sleep and circadian abnormalities, which in turn exacerbate and accelerate neurodegeneration. If so, sleep therapies bear important potential to slow progression in these diseases. FINDINGS: This cycle is challenging to study, as its bidirectional nature renders cause difficult to disentangle from effect. Likewise, well-controlled intervention studies are often impractical in the setting of established neurodegenerative disease. It is this that makes understanding sleep and circadian abnormalities in Huntington's disease (HD) important: as a monogenic fully penetrant neurodegenerative condition presenting in midlife, it provides a rare opportunity to study sleep and circadian abnormalities longitudinally, prior to and throughout disease manifestation, and in the absence of confounds rendered by age and comorbidities. It also provides potential to trial sleep therapies at a preclinical or early disease stage. Moreover, its monogenic nature facilitates the development of transgenic animal models through which to run parallel pre-clinical studies. HD, therefore, provides a key model condition through which to gain new insights into the sleep-neurodegeneration interface. CONCLUSIONS: Here, we begin by summarising contemporary knowledge of sleep abnormalities in HD, and consider how well these parallel those of Alzheimer's and Parkinson's as more common neurodegenerative conditions. We then discuss what is currently known of the sleep-neurodegeneration cyclical relationship in HD. We conclude by outlining key directions of current and future investigation by which to advance the sleep-neurodegeneration field via studies in HD.
INTRODUCTION: Mounting evidence supports the existence of an important feedforward cycle between sleep and neurodegeneration, wherein neurodegenerative diseases cause sleep and circadian abnormalities, which in turn exacerbate and accelerate neurodegeneration. If so, sleep therapies bear important potential to slow progression in these diseases. FINDINGS: This cycle is challenging to study, as its bidirectional nature renders cause difficult to disentangle from effect. Likewise, well-controlled intervention studies are often impractical in the setting of established neurodegenerative disease. It is this that makes understanding sleep and circadian abnormalities in Huntington's disease (HD) important: as a monogenic fully penetrant neurodegenerative condition presenting in midlife, it provides a rare opportunity to study sleep and circadian abnormalities longitudinally, prior to and throughout disease manifestation, and in the absence of confounds rendered by age and comorbidities. It also provides potential to trial sleep therapies at a preclinical or early disease stage. Moreover, its monogenic nature facilitates the development of transgenic animal models through which to run parallel pre-clinical studies. HD, therefore, provides a key model condition through which to gain new insights into the sleep-neurodegeneration interface. CONCLUSIONS: Here, we begin by summarising contemporary knowledge of sleep abnormalities in HD, and consider how well these parallel those of Alzheimer's and Parkinson's as more common neurodegenerative conditions. We then discuss what is currently known of the sleep-neurodegeneration cyclical relationship in HD. We conclude by outlining key directions of current and future investigation by which to advance the sleep-neurodegeneration field via studies in HD.
Authors: B Guarnieri; F Adorni; M Musicco; I Appollonio; E Bonanni; P Caffarra; C Caltagirone; G Cerroni; L Concari; F I I Cosentino; S Ferrara; S Fermi; R Ferri; G Gelosa; G Lombardi; D Mazzei; S Mearelli; E Morrone; L Murri; F M Nobili; S Passero; R Perri; R Rocchi; P Sucapane; G Tognoni; S Zabberoni; S Sorbi Journal: Dement Geriatr Cogn Disord Date: 2012-03-08 Impact factor: 2.959
Authors: Shirin Shafazand; Douglas M Wallace; Kristopher L Arheart; Silvia Vargas; Corneliu C Luca; Henry Moore; Heather Katzen; Bonnie Levin; Carlos Singer Journal: Ann Am Thorac Soc Date: 2017-03
Authors: Paolo Barone; Angelo Antonini; Carlo Colosimo; Roberto Marconi; Letterio Morgante; Tania P Avarello; Eugenio Bottacchi; Antonino Cannas; Gabriella Ceravolo; Roberto Ceravolo; Giulio Cicarelli; Roberto M Gaglio; Rosa M Giglia; Francesco Iemolo; Michela Manfredi; Giuseppe Meco; Alessandra Nicoletti; Massimo Pederzoli; Alfredo Petrone; Antonio Pisani; Francesco E Pontieri; Rocco Quatrale; Silvia Ramat; Rosanna Scala; Giuseppe Volpe; Salvatore Zappulla; Anna Rita Bentivoglio; Fabrizio Stocchi; Giorgio Trianni; Paolo Del Dotto Journal: Mov Disord Date: 2009-08-15 Impact factor: 10.338